

Iowa Department of Human Services



Request for Prior Authorization Cyclosporine Ophthalmic Emulsion 0.1% (Verkazia)

Provider Help Desk | (844) 236-1464 (PLEASE PRINT – ACCURACY IS IMPORTANT)

FAX Completed Form To 1(877) 733-3195

IA Medicaid Member ID #	Patient name		DOB	
Patient address				
Provider NPI	Prescriber name		Phone	
Prescriber address		Fax		
Pharmacy name	Address		Phone	
Prescriber must complete all information above. It must be legible, correct, and complete or form will be returned. Pharmacy NPI Pharmacy fax NDC				
Prior authorization (PA) is required for cyclosporine 0.1% ophthalmic emulsion (Verkazia). Payment will be considered for an FDA approved or compendia indicated diagnosis for the requested drug when the following conditions are met: 1. Request adheres to all FDA approved labeling for requested drug and indication, including age, dosing, contraindications, warnings and precautions, drug interactions, and use in specific populations; and 2. Patient has a diagnosis of moderate to severe vernal keratoconjunctivitis (VKC); and 3. Documentation of an adequate trial (2 to 3 weeks) and therapy failure with a preferred topical dual-acting mast cell stabilizer/topical antihistamine (e.g., olopatadine, azelastine); and 4. Documentation of an adequate trial (2 to 3 weeks) and therapy failure with a preferred topical ophthalmic corticosteroid (e.g., dexamethasone, prednisolone, fluorometholone, loteprednol); and 5. Is prescribed by, or in consultation with an ophthalmologist or optometrist; and 6. Is not prescribed in combination with other ophthalmic cyclosporine products. The required trials may be overridden when documented evidence is provided that use of these agents would be medically contraindicated. Initial requests will be approved for 6 months. Additional authorizations will be considered upon documentation of clinical response to therapy. Non-Preferred				
<u></u>				
	Dosage Instructions Qua	ntity	Days Supply	
	Dosage Instructions Qua	ntity	Days Supply	
Strength	Dosage Instructions Qua	ntity	Days Supply	
Strength			Days Supply	
Strength Diagnosis: Prescriber Specialty: Ophthalm		pecify):		
Strength Diagnosis: Prescriber Specialty: Ophthalm If other, note consultation with ophtha	nologist	pecify):		

Request for Prior Authorization Cyclosporine Ophthalmic Emulsion 0.1% (Verkazia)

(PLEASE PRINT - ACCURACY IS IMPORTANT)

Trial Documentation:

Preferred dual-acting mast cell stabilizer/topical antihistamine:	
Drug Name:	Strength:
Dosing Instructions:	Trial start date:
Preferred topical ophthalmic corticosteroid: Drug Name:	Strength:
Dosing Instructions:	Trial start date:
Medical or contraindication reason to override trial requirements:	
Requests for continuation therapy:	
Has patient demonstrated a positive clinical response to therapy?	
☐ No	
Yes, please describe:	
Attach lab results and other documentation as necessary.	
Prescriber signature (Must match prescriber listed above.)	Date of submission

IMPORTANT NOTE: In evaluating requests for prior authorization the consultant will consider the treatment from the standpoint of medical necessity only. If approval of this request is granted, this does not indicate that the member continues to be eligible for Medicaid. It is the responsibility of the provider who initiates the request for prior authorization to establish by inspection of the member's Medicaid eligibility card and, if necessary by contact with the county Department of Human Services, that the member continues to be eligible for Medicaid.

PAA - 1122 Page 2 of 2